ADCT
Adc Therapeutics SA
Halal Rating :
Last Price
$1.84
Last updated:
Market Cap
-
7D Change
6.98%
1 Year Change
-3.16%
Company Overview
Industries
Exchange
Next Earnings Date
ADC Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors. The company's lead product is ZYNLONTA, which is approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $18.46m | $67.14m | - | $13.12m | 0.00% | 19.54% |
| June 30, 2024 | $17.41m | $59.13m | - | $12.68m | 0.00% | 21.44% |
| March 31, 2024 | $18.05m | $64.16m | - | $12.5m | 0.00% | 19.48% |
Company Impact
Help us evaluate Adc Therapeutics SA's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.